复方丹参滴丸联合拉米夫定治疗活动性肝硬化的疗效观察

目的探讨复方丹参滴丸联合拉米夫定治疗活动性肝硬化的临床疗效。方法将82例活动性肝硬化患者随机分为两组,治疗组42例,口服复方丹参滴丸加拉米夫定治疗。对照组40例,5%葡萄糖注射液250ml加甘利欣注射液30ml静脉点滴,1个月后改用甘利欣胶囊口服治疗。观察治疗前、后两组患者肝功能及治疗前和治疗开始后1、3、6、12个月的HBVDNA变化,比较HBVDNA阴转率。结果治疗后两组患者丙氨酸氨基转移酶、天冬门氨酸氮基转移酶和总胆红素水平间差别均有显著性意义(P<0.05),HBV-DNA的阴转率间差别亦有显著性意义(P<0.05)。结论复方丹参滴丸加拉米夫定对活动性肝硬化有明显的疗效,值得临床推广应用。

复方丹参滴丸治疗冠心病心绞痛的疗效分析

目的:研究并分析治疗冠心病心绞痛患者时使用复方丹参滴丸的效果。方法:收集冠心病心绞痛患者共86例,根据随机分配方案将其分为对照组(43例)和观察组(43例),对照组的治疗药物为硝酸异山梨酯,观察组的治疗药物则为复方丹参滴丸,将两组心电图疗效、同型半胱氨酸、脑钠肽前体、超敏C反应蛋白水平以及血液流变学改善情况进行观察和对比。结果:观察组心电图疗效与对照组相比,差异显著;就同型半胱氨酸、脑钠肽前体、超敏C反应蛋白水平而言,观察组显著低于对照组;而在血液流变学改善情况方面,观察组显著优于对照组(均P<0.05)。结论:在冠心病心绞痛患者的治疗过程中,复方丹参滴丸能够使患者获得更佳疗效,改善血液流变学,值得推广应用。

双黄连粉针配合复方丹参注射液治疗鼻咽癌放疗后疼痛疗效观察

目的 观察双黄连粉针配合复方丹参注射液治疗鼻咽癌放疗后疼痛的临床疗效，探讨其机理作用。方法 ５６例鼻咽癌随机分为２组，双黄连粉针配合复方丹参注射液为治疗组３１例，并与单纯复方丹参注射液治疗２５例为对照组进行对照比较，观察临床止痛效果及生存质量。结果 治疗组总缓解率 ８７． １％，对照组总缓解率 ６４％，２组比较有极显著差异（Ｐ ＜０． ０１）。生存质量变化：治疗组改善率５８％，对照组改善率３６％２组比较有极显著差异（Ｐ＜０．０１）。止痛起效时间治疗组与对照组分别为（０．８２±０．４）ｈ、（１．１２±０．６）ｈ；治愈时间分别为（１０．８２±３．４７）日、（１４．２８±３．１２）日，２组比较有极显著差异（Ｐ＜０．０１）。结论 双黄连粉针具有清热解毒、抗病毒、抗炎，显著提高宿主免疫功能和杀灭病原的双重作用；复方丹参注射液具有活血化瘀、通络止痛功效，改善血液流变性和调节血液黏滞度。２药合用，起到标本兼治的消炎镇痛作用。

复方一枝蒿颗粒儿童用药有效剂量评价

目的:探讨复方一枝蒿颗粒儿童用药的有效性及最佳有效剂量范围,为儿童临床用药的有效性及用法用量提供参考。方法:通过甲型H1N1流行性感冒病毒感染致幼龄小鼠肺炎模型及死亡模型观察复方一枝蒿颗粒的抗病毒作用;采用腹腔毛细血管通透性试验及棉球肉芽肿试验观察其抗炎作用;采用扭体试验观察其镇痛作用;采用金黄色葡萄球菌感染致幼龄小鼠死亡模型观察其抗菌作用,采用脂多糖(LPS)致幼龄家兔发热模型观察其解热作用。结果:复方一枝蒿颗粒0.7、0.9 g生药/(kg·d)2个剂量组可发挥稳定的抗病毒抗菌作用,并可显著抑制小鼠毛细血管通透性及大鼠棉球肉芽肿形成,减少小鼠扭体次数。结论:复方一枝蒿颗粒在0.7~0.9 g生药/(kg·d)剂量范围内对幼龄动物模型具有良好的抗病毒、抗菌、抗炎、镇痛作用。

复方丹参滴丸与心脑舒通胶囊治疗不稳定型心绞痛的疗效比较

目的比较复方丹参滴丸与心脑舒通胶囊治疗不稳定型心绞痛的临床疗效。方法将180例不稳定型心绞痛患者按治疗方法的不同分为治疗组和对照组,每组90例。治疗组采用复方丹参滴丸治疗,对照组采用心脑舒通胶囊治疗。观察2组治疗前、治疗8周后血液流变学指标(红细胞比容、红细胞沉降率、血浆黏度、全血高切黏度、全血低切黏度及纤维蛋白原)、血脂指标(总胆固醇、三酰甘油、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇)的变化及临床疗效、不良反应发生率。结果 2组总有效率比较差异无统计学意义(P>0.05)。与治疗前比较,2组治疗8周后红细胞比容、红细胞沉降率、血浆黏度、全血高切黏度、全血低切黏度及纤维蛋白原水平均明显降低(均P<0.05)。2组均未出现不良反应。结论复方丹参滴丸与心脑舒通胶囊治疗不稳定型心绞痛的疗效相当,均具有改善血液流变学特征的作用,复方丹参滴丸与心脑舒通胶囊均是治疗不稳定型心绞痛的安全、有效的药物。

银杏二萜内酯葡胺注射液合复方丹参胶囊治疗中风后抑郁的疗效观察

目的:探讨银杏二萜内酯葡胺注射液合复方丹参胶囊治疗中风后抑郁的疗效观察。方法:选取2013年1月-2016年12月于我科就诊的中风后抑郁的患者100例作为研究对象,随机分为对照组和观察组,对照组给予常规西医治疗,并给予银杏二萜内酯葡胺注射液治疗,观察组在对照组治疗的基础上再给予复方丹参胶囊治疗,疗程为4周,比较两组患者的治疗前后汉密顿抑郁量表(HAMD)积分,白介素-6(IL-6)以及治疗总有效率。结果:治疗结束后观察组的汉密顿抑郁量表积分低于对照组,差异有统计学意义(P<0.05);观察组IL-6的改善情况优于对照组,差异有统计学意义(P<0.05);观察组的总有效率为70.0%,明显高于对照组的50.0%,差异有统计学意义(P<0.05)。结论:银杏二萜内酯葡胺注射液合复方丹参胶囊治疗中风后抑郁具有良好的临床效果,并且可以改善患者的实验室指标,具有一定的临床意义,值得在临床中推广应用。

Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂) on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis

OBJECTIVE: To investigate the clinical efficacy of Fufang Huangqi decoction(复方黄杞汤剂) in combination with pyridostigmine bromide tablets, prednisone, and tacrolimus in the treatment of type Ⅰ and Ⅱ myasthenia gravis(MG) through changes in the clinical symptom scores of 100 patients with type Ⅰ and Ⅱ MG. This study also aimed to examine dose reductions and discontinuation of these 3 Western medicines after administration of Fufang Huangqi decoction. METHODS: The clinical data on 100 patients with type I or II MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China, between June 2017 and June 2020 were collected. The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets, prednisone, and/or tacrolimus at the time of their hospital visit: the Fufang Huangqi decoction group(group A), the pyridostigmine bromide tablets + Fufang Huangqi decoction group(group B), the pyridostigmine bromide tablets + prednisone + Fufang Huangqi decoction group(group C), and the pyridostigmine bromide tablets + tacrolimus + Fufang Huangqi decoction group(group D). The average treatment time was(15.6 ± 11.5) months(range: 0.5-55 months). Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed. RESULTS: An overall effectiveness rate of 86.00% was achieved in the 100 patients after treatment for(15.6 ± 11.5) months(range 0.5-55 months). The effectiveness rates were 85.71% in group A, 88.24% in group B, 76.92% in group C, and 80.00% in group D. The dosage of pyridostigmine bromide was reduced for 69.12% of the patients in group B for the first time after(4.2 ± 4.1) months, and 45.59% of the patients in group B discontinued pyridostigmine bromide after(8.8 ± 6.1) months. The dosage of pyridostigmine bromide was reduced for 46.15% of the patients in group C for the first time after(5.3 ± 3.4) months, and 23.08% of the patients in group C discontinued pyridostigmine bromide after(19.8 ± 11.0) months;76.92% reduced hormone dosage after(2.8 ± 1.9) months, and 23.08% discontinued hormone treatment after(6.7 ± 2.9) months. The dosage of pyridostigmine bromide was reduced for 1 patient in group D after 1 month;this patient discontinued pyridostigmine bromide after 3 months and reduced tacrolimus dosage after 5 months. One patient in group D discontinued pyridostigmine bromide and tacrolimus on his own initiative at 0.5 months and took Fufang Huangqi decoction for 2 months without discontinuing Western medicine. CONCLUSION: Fufang Huangqi decoction is effective for the treatment of type Ⅰ and Ⅱ MG and improves the associated clinical symptoms. Moreover, this agent is conducive to dose reductions and discontinuation of basic Western medicines, thereby reducing the side effects experienced by patients.

复方肝宁保肝及提高免疫功能的作用

复方肝宁是由黄芪、丹参、郁金、黄精等8味中药组成的经验方制成口服液,它对四氯化碳引起的小鼠,大鼠急性肝损伤有明显的保护作用,能降低转氨酶(ALT),使磺溴酞钠(BSP)潴留减少,病理组织学也相应改善,对硫代乙酰胺和 D-半乳糖胺引起急性肝损也有保护作用,并对α-萘异硫氰酸酯引起的小鼠、大鼠实验性黄疸肝损模型有降酶和降低血清胆红素作用。复方肝宁对四氯化碳诱发实验性肝硬化模型有降酶和使肝细胞变性、坏死及肝硬化明显减轻,能提高正常小鼠对碳粒的廓清指数和血清溶血素,增强免疫功能。

阿托伐他汀联合复方丹参滴丸治疗老年高脂血症疗效观察

目的:观察阿托伐他汀联合复方丹参滴丸治疗老年高脂血症的临床疗效。方法:选择老年高脂血症患者100例为研究对象,随机分为治疗组和对照组各50例,入选病例均行常规低脂饮食。治疗组患者口服阿托伐他汀10mg·qd及复方丹参滴丸10片tid治疗,对照组患者口服阿托伐他汀20mg·qd治疗,共治疗8周,观察两组治疗前后TC、TG、HDL-C水平变化。结果:治疗组降低TC、TG和升高HDL-C的有效率分别为94.0%、88.0%、90.0%,对照组分别为74.0%、70.0%、74.0%,两组差异显著(P<0.05),具有统计学意义。结论:阿托伐他汀联合复方丹参滴丸治疗老年高脂血症安全有效,值得临床推广应用。

Recommendations on the Clinical Use of Compound Danshen Dripping Pills

Currently in China, about 290 million people have cardiovascular disease （CVD）. Cardiovascular-relevant morbidity and mortality in Chinese population rose quickly, and increasing nunlber of the patients has brought about a serious health problem to the society. CVD has become the leading cause of death in China, and among the overall mortality, two in every five patients have CVD. Fortunately,

复方丹参注射液致药物热的原因探讨

目的:探讨复方丹参注射液致药物热的原因。方法:依据文献和药典标准对样品进行细菌内毒素和有关物质的检查。结果:有药物热反应的样品其细菌内毒素检查为阳性。结论:复方丹参注射液所致药物热与细菌内毒素相关。

丹参酮ⅡA、人参皂苷Rg1和人参皂苷Rb1配伍对平滑肌细胞的抑制作用

目的:探讨丹参酮ⅡA与复方丹参方中另两种有效成分人参皂苷Rg1和人参皂苷Rb1不同剂量配伍时对血管平滑肌细胞(VSMC)增殖、迁移的作用。方法:血管紧张素Ⅱ(AngⅡ)0.1μmol/L诱导大鼠VSMC增殖,随后采用MTT法检测增殖细胞的活性、细胞划痕损伤实验检测细胞迁移数目、流式细胞术检测细胞周期的分布。结果:两味药配伍组中Rg110μmol/L+Rb17μmol/L、三味药配伍组中ⅡA 4μmol/L+Rg11μmol/L+Rb17μmol/L抑制VSMC增殖的作用显著高于其他各组,且可以抑制细胞迁移,使细胞阻滞在G1期(P<0.01)。结论:上述两种配伍可以明显抑制VSMC的增殖、迁移。

复方丹参药物血清对人胃癌细胞增殖的抑制作用

目的探讨复方丹参药物血清对入胃癌细胞增殖的抑制作用。方法给予体外培养人胃癌细胞复方丹参药物血清,用克隆形成法和流式细胞仪检测对细胞分裂增殖和细胞凋亡的影响。结果复方丹参药物血清(3.6、7.3、15g/kg)和5-氟脲嘧啶(5-FU)组克隆数比对照组克隆数(78.67±2.2)明显减少,克隆形成抑制率分别为13.1%、46.6%、64.0%和40.7%.复方丹参药物血清(3.6、7.3、15g/kg)组和5-FU凋亡率比对照组凋亡率(7.4%)明显增加,分别为:16.3%、24.2%、31.1%和22.1%。结论复方丹参药物血清对人胃癌细胞分裂增殖具有明显的毒性和抑制作用。